227 related articles for article (PubMed ID: 20400373)
1. HIV-associated lipodystrophy: from fat injury to premature aging.
Caron-Debarle M; Lagathu C; Boccara F; Vigouroux C; Capeau J
Trends Mol Med; 2010 May; 16(5):218-29. PubMed ID: 20400373
[TBL] [Abstract][Full Text] [Related]
2. Disorders of fat partitioning in treated HIV-infection.
Martínez E
Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):415-27. PubMed ID: 21663836
[TBL] [Abstract][Full Text] [Related]
3. [Lipodystrophies related to antiretroviral treatment of HIV infection].
Capeau J; Caron M; Vigouroux C; Cervera P; Kim M; Maachi M; Lagathu C; Bastard JP
Med Sci (Paris); 2006 May; 22(5):531-6. PubMed ID: 16687123
[TBL] [Abstract][Full Text] [Related]
4. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study.
Kim MJ; Leclercq P; Lanoy E; Cervera P; Antuna-Puente B; Maachi M; Dorofeev E; Slama L; Valantin MA; Costagliola D; Lombes A; Bastard JP; Capeau J
Antivir Ther; 2007; 12(8):1273-83. PubMed ID: 18240867
[TBL] [Abstract][Full Text] [Related]
5. [Metabolic side effects of antiretroviral therapy].
van der Valk M; Reiss P
Ned Tijdschr Geneeskd; 2008 May; 152(22):1260-4. PubMed ID: 18590059
[TBL] [Abstract][Full Text] [Related]
6. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
7. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo.
Lagathu C; Kim M; Maachi M; Vigouroux C; Cervera P; Capeau J; Caron M; Bastard JP
Biochimie; 2005 Jan; 87(1):65-71. PubMed ID: 15733739
[TBL] [Abstract][Full Text] [Related]
8. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
[TBL] [Abstract][Full Text] [Related]
9. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
Nolan D; Hammond E; James I; McKinnon E; Mallal S
Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
[TBL] [Abstract][Full Text] [Related]
10. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J
Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860
[TBL] [Abstract][Full Text] [Related]
11. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
[TBL] [Abstract][Full Text] [Related]
12. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
[TBL] [Abstract][Full Text] [Related]
13. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues.
Caron M; Auclairt M; Vissian A; Vigouroux C; Capeau J
Antivir Ther; 2008; 13(1):27-38. PubMed ID: 18389896
[TBL] [Abstract][Full Text] [Related]
14. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Falutz J; Allas S; Blot K; Potvin D; Kotler D; Somero M; Berger D; Brown S; Richmond G; Fessel J; Turner R; Grinspoon S
N Engl J Med; 2007 Dec; 357(23):2359-70. PubMed ID: 18057338
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy.
Zanone Poma B; Riva A; Nasi M; Cicconi P; Broggini V; Lepri AC; Mologni D; Mazzotta F; Monforte AD; Mussini C; Cossarizza A; Galli M;
AIDS; 2008 Sep; 22(14):1769-78. PubMed ID: 18753860
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
[TBL] [Abstract][Full Text] [Related]
18. Adipocyte dysfunction in response to antiretroviral therapy: clinical, tissue and in-vitro studies.
Caron M; Vigouroux C; Bastard JP; Capeau J
Curr Opin HIV AIDS; 2007 Jul; 2(4):268-73. PubMed ID: 19372898
[TBL] [Abstract][Full Text] [Related]
19. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations.
Caron-Debarle M; Boccara F; Lagathu C; Antoine B; Cervera P; Bastard JP; Vigouroux C; Capeau J
Curr Pharm Des; 2010 Oct; 16(30):3352-60. PubMed ID: 20687886
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
